Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer

International Journal of Breast Cancer - Tập 2011 - Trang 1-6 - 2011
Jorge Luis Soriano1, Noyde Batista1, Eduardo Santiesteban2, M.C.P. Lima1, Javier Ernesto Barreras González1, Robin García1, Yohanka Zarza1, María V. López1, Myriam Rodríguez1, Jorge L. Loys1, Narciso Montejo1, Frank V. Aguirre2, Amparo Macías3, Ana María Vázquez3
1Oncology Service, Hermanos Amejeiras Hospital, Havana 10300, Cuba
2Oncology Service, José R. López Tabrane Hospital, Matanzas 40100, Cuba
3Clinical Division, Center of Molecular Immunology, Havana 11600, Cuba

Tóm tắt

The use of low doses of cytotoxic agents continuously for prolonged periods is an alternative for the treatment of patients with metastatic breast cancer who have developed resistance to conventional chemotherapy. The combination of metronomic chemotherapy with therapeutic vaccines might increase the efficacy of the treatment. Twenty one patients with metastatic breast cancer in progression and a Karnosky index ≥60%, were treated with metronomic chemotherapy (50 mg of cyclophospamide orally daily and 2.5 mg of methotrexate orally bi-daily), in combination with five bi-weekly subcutaneous injections of 1 mg of aluminum hydroxide-precipitated 1E10 anti-idiotype MAb (1E10-Alum), followed by reimmunizations every 28 days. Five patients achieved objective response, eight showed stable disease and eight had disease progression. Median time to progression was 9,8 months, while median overall survival time was 12,93 months. The median duration of the response (CR+PR+SD) was 18,43 months (12,20–24,10 months), being higher than 12 months in 76,9% of the patients. Overall toxicity was generally mild. Metronomic chemotherapy combined with 1E10-Alum vaccine immunotherapy might be a useful therapeutic option for the treatment of metastatic breast cancer due to its potential impact on survival and patient quality of live, low toxicity and advantages of the administration.

Từ khóa


Tài liệu tham khảo

10.1016/S0959-8049(96)00423-6

10.1158/0008-5472.CAN-04-0580

10.1200/JCO.2005.12.017

1999, Cancer Conference Highlights, 3, 2

1999, Clinical Cancer Research, 5, 2726

2000, Cancer Research, 60, 1878

10.1006/jtbi.2003.3162

10.1158/0008-5472.CAN-03-3126

2004, Nature Reviews Cancer, 4, 423, 10.1038/nrc1369

2009, Revista Cubana de Medicina, 48

1998, Hybridoma, 17, 527, 10.1089/hyb.1998.17.527

1995, Hybridoma, 14, 551, 10.1089/hyb.1995.14.551

2002, Journal of Immunology, 168, 2523, 10.4049/jimmunol.168.5.2523

2007, Cancer Biology and Therapy, 6, 145, 10.4161/cbt.6.2.3574

2000, Oncology Reports, 7, 751

10.1016/S1521-6616(03)00036-6

10.1007/s10549-009-0399-9

10.1023/A:1013172910858

10.1002/(SICI)1097-0142(19990101)85:1<104::AID-CNCR15>3.0.CO;2-R

10.1097/01.cad.0000224454.46824.fc

10.1158/0008-5472.CAN-05-2598

2002, Clinical evidence, 1785

2000, Journal of Clinical Investigation, 105, 1045, 10.1172/JCI9872

10.1038/nrc1613

10.1006/clim.2001.5123

2004, Breast Cancer Research, 6, R275, 10.1186/bcr787

2006, International journal of molecular medicine., 17, 1045

10.1007/s00262-006-0225-8

10.1097/01.cji.0000188502.11348.34

Thông tin
Thông tin xuất bản

International Journal of Breast Cancer

Tập 2011

1-6

Thông tin tác giả